.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX22_Leniolisib.Leniolisib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX22_Leniolisib.Leniolisib| name: | Leniolisib |
| ATC code: | L03AX22 | route: | oral |
| n-compartments | 2 |
Leniolisib is an oral selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency disorder. It is approved for use in the United States and the European Union in patients aged 12 years and older with APDS.
Pharmacokinetic parameters for leniolisib reported in APDS patients (male and female, ages 12 and older) after oral administration of a 70 mg twice daily dose.